Table 3 Clinical features of patients with MRSA bacteraemia associated with survivor and non-survivor^a

Patient demographics

 Median age (years)

76.5 ± 11.5

67.8 ± 18.2

0.114

 Male sex

7

20

0.838

hVISA

1

13

0.046

Charlson comorbidity score

2.4 ± 1.4

3.2 ± 2.1

0.207

SOFA score

5.9 ± 3.0

9.1 ± 3.8

0.009

Hemodialysis

2

19

0.016

Comorbidity

 Chronic renal disease

3 (23.1)

15 (42.9)

0.208

 Solid organ malignancy

2

6

0.885

 Hematological malignancy

0

2

0.379

 Diabetes mellitus

7

11

0.154

 Liver cirrhosis

1

8

0.232

 Heart disease

3

6

0.640

 Chronic pulmonary disease

0

2

0.379

 Cerebrovascular accident

7

5

0.005

Primary site of infection

0.72

 Catheter-related infection

3

4

 Pneumonia

6

18

 Surgical wound infection

1

2

 Other

0

3

 Unknown

3

8

CRP

139.5 ± 84.7

135.6 ± 88.5

0.897

Albumin

2.6 ± 0.8

2.4 ± 0.5

0.425

Prior vancomycin therapy

4

11

0.627

Adequate antibiotics treatment

3

12

0.48

Shock after infection

2

15

0.077

agr dysfunction

1 (7.7)

12 (34.3)

0.065

Vancomycin MIC (Etest)

0.111

 1 mg/L

1

5

 1.5 mg/L

8

10

 2 mg/L

4

20